熱門資訊> 正文
Jazz Pharmaceuticals定价8.5亿美元高级票据
2024-09-04 18:17
- Jazz Pharmaceuticals (NASDAQ:JAZZ) priced $850M aggregate principal amount of 3.125% exchangeable senior notes due 2030 in a private offering by its subsidiary Jazz Investments I.
- The issuer also granted the initial purchasers an option to purchase additional $150M notes.
- The sale of the notes is expected to close on September 6, 2024.
- The company also repurchased ~$150M of its ordinary shares from purchasers of the notes in privately negotiated transactions.
More on Jazz Pharmaceuticals
- Jazz Pharmaceuticals plc 2024 Q2 - Results - Earnings Call Presentation
- Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
- Avadel says court denies Jazz Pharma request on lumryz in narcolepsy (update)
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
